Trump announces trade deal with EU following months of negotiations
On Thursday, UBS analysts maintained their Neutral rating on Bristol-Myers Squibb Co. (NYSE:BMY), a prominent pharmaceutical company with a market capitalization of nearly $120 billion and current stock price of $59.09, maintaining their price target of $60.00. According to InvestingPro analysis, BMY is currently trading below its Fair Value, suggesting potential upside opportunity. The company boasts an impressive 75% gross profit margin and offers a substantial 4.19% dividend yield. The focus of their commentary was on the recent performance of Cobenfy, a product in the company’s portfolio, which has seen a leveling off in total prescriptions (TRx) over the past two weeks. This stagnation has raised questions among investors regarding the achievability of first-quarter and full-year 2025 consensus forecasts. With annual revenue of $48.3 billion and a history of maintaining dividend payments for 55 consecutive years, BMY has demonstrated resilience in navigating market challenges.
The analysis of IQVIA data led UBS analysts to a positive outlook despite the initial concerns. They noted that Cobenfy’s launch has been more successful compared to similar antipsychotics like Lyablvi and Caplyta, which also experienced volatility in their early stages. UBS analysts project that, even with a conservative estimate of volume growth, Cobenfy could reach approximately 15,000 TRx in the first quarter of 2025 and about 122,000 TRx for the full year.
Taking into account discounts ranging from 25-35%, UBS analysts estimate that Cobenfy’s sales could realistically hit between $18 million to $21 million in the first quarter of 2025, and between approximately $150 million to $170 million for the full year. These figures align closely with UBS’s own estimates of $17 million for the first quarter and $165 million for the year, as well as the consensus estimates of $16.8 million for the first quarter and $168 million for the year.
The analysts also highlighted that their estimates do not include any potential benefits from product stocking or a possible increase in sales in the second half of 2025, which Bristol-Myers Squibb has suggested could provide additional upside to Cobenfy’s performance. For deeper insights into BMY’s valuation metrics, growth potential, and comprehensive financial analysis, investors can access the detailed Pro Research Report available on InvestingPro, which offers expert analysis of over 1,400 US stocks.
In other recent news, Bristol Myers Squibb has reported several significant developments. The European Commission has expanded its approval for the company’s CAR-T cell therapy, Breyanzi, to include adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This decision follows the high response rates demonstrated in the Phase 2 TRANSCEND FL study. Additionally, Bristol Myers Squibb has entered into an agreement to acquire 2seventy bio for approximately $286 million in an all-cash transaction, with the deal expected to close in the second quarter of 2025. In another advancement, the European Commission has approved the Opdivo-Yervoy combination therapy for advanced liver cancer, based on improved survival rates shown in the Phase 3 CheckMate -9DW study. Furthermore, Bristol Myers Squibb’s Board of Directors has declared a quarterly dividend of $0.62 per share on its common stock and $0.50 per share on its convertible preferred stock. These dividends reflect the company’s ongoing financial health and commitment to delivering shareholder value.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.